Overview
Orphinic Scientific is a biopharma holding that focuses on the clinical development of innovative therapeutics, MedTech, and e-Health projects. The company actively manages a portfolio of promising biotech projects, including a potent analgesic formulation and a first-in-class gene therapy for rare ischemic limb diseases. They also partner with large pharmaceutical players to verify research hypotheses and facilitate project transactions.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2020-09-01. Active
03 2490 0005 0000 4600 8737 7972- 68 2490 0005 0000 4530 3477 6850
- 95 2490 0005 0000 4600 1201 8277
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Apr 11, 2025 | Commercial Companies Code notice | |
| Sep 2, 2024 | Commercial Companies Code notice |
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jul 24, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,282$1,282 | Prezydent Miasta Stołecznego Warszawy |
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
In the case of a one-person management board, the company is represented by the sole member of the management board. If the management board is multi-member, two members of the management board jointly or one member of the management board jointly with a commercial proxy are authorised to make declarations of will and sign on behalf of the company.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Subsidiaries
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| FamicordtxS.A. | $1,365,068.41 | famicordtx.com | ||
| BioceltixS.A. | $616,315.97 | bioceltix.com | ||
| OrthogetS.A. | $532,980.53 | orthoget.com | ||
| BiottsS.A. | $372,115.60 | biotts.com | ||
| Green ZebrasS.A. | $328,658.91 | whygreenzebras.pl | ||
| Medicofarma BiotechS.A. | $314,882.33 | medicofarmabiotech.pl | ||
| Explorna Therapeuticssp. z o.o. | $304,662.00 | explorna.com | ||
| CCTSsp. z o.o. | $281,193.31 | ccts.pl | ||
| Frontline BiosciencesS.A. | $219,186.29 | frontlinebiosciences.com | ||
| NanosanguisS.A. | $192,701.50 | nanosanguis.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-04-09 | Address change (Ul. Postępu 21b, 02-676, Warszawa → Ul. Stanisława Żaryna 2b, 02-593, Warszawa) | |
| 2026-04-09 | Share capital change (440,562.80 PLN → 506,090.90 PLN) | |
| 2025-04-28 | Share capital change (438,542.50 PLN → 440,562.80 PLN) | |
| 2025-02-18 | Share capital change (435,149.30 PLN → 438,542.50 PLN) | |
| 2024-12-11 | Share capital change (421,815.90 PLN → 435,149.30 PLN) |
FAQ
Last updated: 2026-04-09